Health · Hardware
Lyvgen Biopharma
Lyvgen Biopharma is a Shanghai-based clinical-stage immuno-oncology company founded in 2016 by veteran oncology scientist Dr. Jieyi Wang. It builds agonist antibodies - drugs that switch the immune system on rather than release its brakes - using a proprietary xLinkAb platform designed to concentrate immune activation inside tumors while limiting toxicity elsewhere. Its lead program, the CD137/4-1BB agonist antibody LVGN6051 (exlinkibart), is in Phase Ib/II trials in the US and China, including combinations with Merck's Keytruda, alongside a CD40 agonist (LVGN7409), a PD-1 blocker (LVGN3616), and bispecific candidates. Backed by IDG Capital and others through a Series C, Lyvgen runs R&D in Shanghai, a CMC/manufacturing center in Suzhou, and clinical and business development teams spanning China and the US.